Dr. Marianne Koritzinsky Publications

  1. Chowdhury, S, Yung, E, Pintilie, M, Muaddi, H, Chaib, S, Yeung, M, Fusciello, M, Sykes, J, Pitcher, B, Hagenkort, A et al. (2016). MATE2 Expression Is Associated with Cancer Cell Response to Metformin. PLoS ONE11,e0165214.
  2. Rey, S, Schito, L, Koritzinsky, M, Wouters, BG (2017). Molecular targeting of hypoxia in radiotherapy. Adv. Drug Deliv. Rev.109,45-62.
  3. Koritzinsky, M, Koch, CA, Riley, B, Beauchemin, N, Johnston, G, Johnston, M, Koropatnick, J, Loiselle, CG, Maslowska, M, McCormick, C et al. (2016). From Solo in the Silo to Strategic Training Programs. CBE Life Sci Educ15,le1.
  4. Hill, RP, Bristow, RG, Fyles, A, Koritzinsky, M, Milosevic, M, Wouters, BG (2015). Hypoxia and Predicting Radiation Response. Semin Radiat Oncol25,260-72.
  5. Koritzinsky, M (2015). Metformin: A Novel Biological Modifier of Tumor Response to Radiation Therapy. Int. J. Radiat. Oncol. Biol. Phys.93,454-64.
  6. Hunter, FW, Young, RJ, Shalev, Z, Vellanki, RN, Wang, J, Gu, Y, Joshi, N, Sreebhavan, S, Weinreb, I, Goldstein, DP et al. (2015). Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs. Cancer Res.75,4211-23.
  7. Ravishankar, B, Liu, H, Shinde, R, Chaudhary, K, Xiao, W, Bradley, J, Koritzinsky, M, Madaio, MP, McGaha, TL (2015). The amino acid sensor GCN2 inhibits inflammatory responses to apoptotic cells promoting tolerance and suppressing systemic autoimmunity. Proc. Natl. Acad. Sci. U.S.A.112,10774-9.
  8. van den Beucken, T, Koch, E, Chu, K, Rupaimoole, R, Prickaerts, P, Adriaens, M, Voncken, JW, Harris, AL, Buffa, FM, Haider, S et al. (2014). Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. Nat Commun5,5203.
  9. Pettersen, EO, Ebbesen, P, Gieling, RG, Williams, KJ, Dubois, L, Lambin, P, Ward, C, Meehan, J, Kunkler, IH, Langdon, SP et al. (2015). Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. J Enzyme Inhib Med Chem30,689-721.
  10. Chan, N, Ali, M, McCallum, GP, Kumareswaran, R, Koritzinsky, M, Wouters, BG, Wells, PG, Gallinger, S, Bristow, RG (2014). Hypoxia provokes base excision repair changes and a repair-deficient, mutator phenotype in colorectal cancer cells. Mol. Cancer Res.12,1407-15.
  11. Mujcic, H, Hill, RP, Koritzinsky, M, Wouters, BG (2014). Hypoxia signaling and the metastatic phenotype. Curr. Mol. Med.14,565-79.
  12. Joshua, AM, Zannella, VE, Downes, MR, Bowes, B, Hersey, K, Koritzinsky, M, Schwab, M, Hofmann, U, Evans, A, van der Kwast, T et al. (2014). A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer. Prostate Cancer Prostatic Dis.17,252-8.
  13. Martin, RM, Kerr, M, Teo, MT, Jevons, SJ, Koritzinsky, M, Wouters, BG, Bhattarai, S, Kiltie, AE (2014). Post-transcriptional regulation of MRE11 expression in muscle-invasive bladder tumours. Oncotarget5,993-1003.
  14. Koritzinsky, M, Levitin, F, van den Beucken, T, Rumantir, RA, Harding, NJ, Chu, KC, Boutros, PC, Braakman, I, Wouters, BG (2013). Two phases of disulfide bond formation have differing requirements for oxygen. J. Cell Biol.203,615-27.
  15. Zannella, VE, Dal Pra, A, Muaddi, H, McKee, TD, Stapleton, S, Sykes, J, Glicksman, R, Chaib, S, Zamiara, P, Milosevic, M et al. (2013). Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. Clin. Cancer Res.19,6741-50.
  16. Mujcic, H, Nagelkerke, A, Rouschop, KM, Chung, S, Chaudary, N, Span, PN, Clarke, B, Milosevic, M, Sykes, J, Hill, RP et al. (2013). Hypoxic activation of the PERK/eIF2α arm of the unfolded protein response promotes metastasis through induction of LAMP3. Clin. Cancer Res.19,6126-37.
  17. Koritzinsky, M, Wouters, BG (2013). The roles of reactive oxygen species and autophagy in mediating the tolerance of tumor cells to cycling hypoxia. Semin Radiat Oncol23,252-61.
  18. Muaddi, H, Chowdhury, S, Vellanki, R, Zamiara, P, Koritzinsky, M (2013). Contributions of AMPK and p53 dependent signaling to radiation response in the presence of metformin. Radiother Oncol108,446-50.
  19. Cojocari, D, Vellanki, RN, Sit, B, Uehling, D, Koritzinsky, M, Wouters, BG (2013). New small molecule inhibitors of UPR activation demonstrate that PERK, but not IRE1α signaling is essential for promoting adaptation and survival to hypoxia. Radiother Oncol108,541-7.
  20. Rouschop, KM, Dubois, LJ, Keulers, TG, van den Beucken, T, Lambin, P, Bussink, J, van der Kogel, AJ, Koritzinsky, M, Wouters, BG (2013). PERK/eIF2α signaling protects therapy resistant hypoxic cells through induction of glutathione synthesis and protection against ROS. Proc. Natl. Acad. Sci. U.S.A.110,4622-7.
Search PubMed